Cefepime Dihydrochloride Monohydrate
(Synonyms: 头孢吡肟盐酸盐) 目录号 : GC13111
A cephalosporin antibiotic
Cas No.:123171-59-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefepime Dihydrochloride Monohydrate is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria[1].
Cefepime is an extended-spectrum parenteral cephalosporin antibiotic active in vitro against a broad spectrum of gram-positive and gram-negative aerobic bacteria. Cefepime has a decreased propensity to induce beta-lactamases compared with other beta-lactam antibiotics[1].
Cefepime has a pharmacokinetic disposition similar to that of other renally eliminated cephalosporins, with a half-life of approximately 2 hours. Cefepime has demonstrated clinical efficacy against a variety of infections, including urinary tract infections, pneumonia, and skin and skin structure infections. Cefepime is generally well tolerated[2].
References:
[1]. Neu, H.C., Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med, 1996. 100(6A): p. 68S-75S.
[2]. Wynd, M.A. and J.A. Paladino, Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother, 1996. 30(12): p. 1414-24.
| Cas No. | 123171-59-5 | SDF | |
| 别名 | 头孢吡肟盐酸盐 | ||
| 化学名 | (1S,8R)-8-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-4-((1-methylpyrrolidin-1-ium-1-yl)methyl)-7-oxo-2-thiabicyclo[4.2.0]oct-4-ene-5-carboxylate dihydrochloride hydrate | ||
| Canonical SMILES | NC1=NC(/C(C(N[C@H]2[C@]3([H])C(C(C([O-])=O)=C(C[N+]4(C)CCCC4)CS3)C2=O)=O)=N/OC)=CS1.Cl.Cl.O | ||
| 分子式 | C19H28Cl2N6O6S2 | 分子量 | 571.5 |
| 溶解度 | ≥ 57.1mg/mL in DMSO | 储存条件 | 4°C, away from moisture and light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7498 mL | 8.7489 mL | 17.4978 mL |
| 5 mM | 0.35 mL | 1.7498 mL | 3.4996 mL |
| 10 mM | 0.175 mL | 0.8749 mL | 1.7498 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。